These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16772206)

  • 21. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide: from the Gila monster to the pharmacy.
    Triplitt C; Chiquette E
    J Am Pharm Assoc (2003); 2006; 46(1):44-52; quiz 53-5. PubMed ID: 16529340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
    Ghazi T; Rink L; Sherr JL; Herold KC
    Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].
    Perusicová J
    Vnitr Lek; 2008 Apr; 54(4):377-86. PubMed ID: 18630617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
    Calara F; Taylor K; Han J; Zabala E; Carr EM; Wintle M; Fineman M
    Clin Ther; 2005 Feb; 27(2):210-5. PubMed ID: 15811484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies for diabetes: pramlintide and exenatide.
    Jones MC
    Am Fam Physician; 2007 Jun; 75(12):1831-5. PubMed ID: 17619527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
    Wajcberg E; Tavaria A
    Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
    Raman VS; Mason KJ; Rodriguez LM; Hassan K; Yu X; Bomgaars L; Heptulla RA
    Diabetes Care; 2010 Jun; 33(6):1294-6. PubMed ID: 20332358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.